Arcellx President Sells $10M Worth of Shares After Acquisition Announcement
Key Points
ACLX share prices have soared nearly 75% in 2026 due to the recent announcement that Arcellx will be acquired.
The acquisition will turn Arcellx back private, after only being on the stock market for four years.
- 10 stocks we like better than Arcellx ›
Rami Elghandour, President of Arcellx (NASDAQ:ACLX), sold 89,916 shares for approximately $10.24 million on Feb. 27, 2026, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 89,916 |
| Transaction value | $10.2M |
| Post-transaction shares (direct) | 276,051 |
| Post-transaction shares (indirect) | 416,500 |
| Post-transaction value (direct ownership) | ~$31.41M |
Transaction value based on SEC Form 4 weighted average purchase price ($113.92); post-transaction value based on Feb. 27, 2026 market close ($113.79).
Key questions
- How does this transaction compare to Elghandour's previous sell activity?
This sale of 89,916 shares is notably larger than his historical median sell size of 38,300 shares since January 2025. - What impact does the sale have on the insider's ownership profile?
Following the sale, Elghandour retains 276,051 shares in direct ownership and maintains 416,500 shares indirectly through a spousal trust, resulting in continued material exposure to Arcellx equity.
Company overview
| Metric | Value |
|---|---|
| Price | $113.79 |
| Market capitalization | $6.65 billion |
| Net Loss (TTM) | -$228.93 million |
| 1-year price change | 75.55% |
*Price and 1-year performance are calculated using Feb. 28, 2026, as the reference date.
Company snapshot
Arcellx, Inc. is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer and other incurable diseases. The company primarily works with oncology healthcare providers and patients with difficult-to-treat cancers across the United States and select global markets.
What this transaction means for investors
Although ACLX share prices have soared, the stock will soon be delisted, as on Feb. 23, 2026, the company announced that it would be acquired by Gilead Sciences (NASDAQ:GILD), another global biopharmaceutical company. While there is no current expected date for the transaction to be finalized, the acquisition is estimated to be worth $7.8 billion, with Gilead purchasing Arcellx at $115 per share and a contingent value right of $5 per share.
The immunotherapy provider also recently achieved a breakthrough with one of its top clinical-stage projects, advancing its multiple myeloma treatment to Phase 2 development. Another of Arcellx’s biggest developments is a blood cancer immunotherapy awaiting FDA approval, with a decision expected by December 2026.
If the treatment is proven successful, it would be a major product in the healthcare space and a significant revenue generator for Arcellx. However, with the merger on the way, it’s difficult to say how long investors have to trade shares before the company is delisted.
Should you buy stock in Arcellx right now?
Before you buy stock in Arcellx, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Arcellx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $519,015!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,086,211!*
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 2, 2026.
Adé Hennis has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
